The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization
Open accessAbstract
Human serum albumin nanoparticles (HSA-NPs) are widely-used drug delivery systems with applications in various diseases, like cancer. For intravenous administration of HSA-NPs, the particle size, surface charge, drug loading and in vitro release kinetics are important parameters for consideration. This study focuses on the development of stable HSA-NPs containing the anti-cancer drug paclitaxel (PTX) via the emulsion-solvent evaporation method using a high-pressure homogenizer. The key parameters for the preparation of PTX-HSA-NPs are: the starting concentrations of HSA, PTX and the organic solvent, including the homogenization pressure and its number cycles, were optimized. Results indicate a size of 143.4 ± 0.7 nm and 170.2 ± 1.4 nm with a surface charge of −5.6 ± 0.8 mV and −17.4 ± 0.5 mV for HSA-NPs and PTX-HSA-NPs (0.5 mg/mL of PTX), respectively. The yield of the PTX-HSA-NPs was ~93% with an encapsulation efficiency of ~82%. To investigate the safety and effectiveness of the PTX-HSA-NPs, an in vitro drug release and cytotoxicity assay was performed on human breast cancer cell line (MCF-7). The PTX-HSA-NPs showed dose-dependent toxicity on cells of 52%, 39.3% and 22.6% with increasing concentrations of PTX at 8, 20.2 and 31.4 μg/mL, respectively. In summary, all parameters involved in HSA-NPs’ preparation, its anticancer efficacy and scale-up are outlined in this research article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
Interactive Association of Drugs Binding to Human Serum Albumin
Yang, F., Zhang, Y., & Liang, H. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033580 · Cited by 376
Cited by
A Review of Curcumin and Its Derivatives as Anticancer Agents
Tomeh, M. A., Hadianamrei, R., & Zhao, X. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051033 · Cited by 949
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
Protein Nanoparticles: Promising Platforms for Drug Delivery Applications
Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01098 · Cited by 308
Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments
Kolarikova, M., Hosikova, B., Dilenko, H., Barton‐Tomankova, K., Valkova, L., Bajgar, R., Malina, L., & Kolarova, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21935 · Cited by 282
Metadata
- Authors
- Lomis, N., Westfall, S., Farahdel, L., Malhotra, M., Shum-Tim, D., & Prakash, S.
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2016-06-15
- Volume
- 6
- Issue
- 6
- Pages
- 116
- ISSN
- 2079-4991 (ISSN-L)
- OpenAlex
- W2430048569
- Cited by
- 187
- References
- 4
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization. https://app.cochat.ai/papers/10.3390/nano6060116
- The paper
- Lomis, N., Westfall, S., Farahdel, L., Malhotra, M., Shum-Tim, D., & Prakash, S. (2016). Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization. Nanomaterials. https://doi.org/10.3390/nano6060116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.